Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anavex Life Sciences Corp. (AVXL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Following
Visitors trend2W10W9M
Quote Lookup
8.16+0.04 (+0.49%)
As of 04:00PM EDT. Market open.
9.01 +0.85 (+10.42%)
After hours: 4:24PM EDT....HUH???
RedShoulder
https://www.nbcnews.com/news/amp/rcna100011
I predict that the less than 1 in 10 will become 0 in 10 once 2-73 Blarcamesine is approved and in the market for one year. Biogen will pull the drug because of adverse side effects, IV injections at the doctors office, low efficacy, and brain scans monitoring for bleeding and brain swelling; because of all those reasons it will be driving what few patients they do treat over to 2-73 Blarcamesine.
Biogen will eventually pull their AD drugs when the revenue is so low that it cannot justify the cost to run the program.
boi568
That seems to leave only a couple of real possibilities: Either Anavex is analyzing so many variables -- and there may be a *lot* of variables, given the genomics and possible new biomarkers -- that the job is still going on (or very recently concluded), and/or the FDA has questions, or results are being withheld for partnership reasons. In other words, there are the possibilities of a delay for FDA or business reasons.
Meanwhile, AVXL continues the science w/no contradictions, unlike the entire Amyloid AD field of thinking...they still whistle past the graveyard...w/FDA pump attached.
Let's get back to work and have a better day today. The Rett kids and families are counting on us.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105170/
Interesting for Anavex 3-71
Talon38 If everyone of us investors would notice that the big three institutional entities, Blackrock, State Street and Vanguard have increased their quarterly share count regularly, we would sleep easier.
BINGO, EXCELLENT OBSERVATION...THX Talon...
Plexrec
"This is not acting like a can’t miss stock"
8.62-0.32 (-3.58%)
At close: August 16 04:00PM EDT
8.83 +0.21 (+2.44%)
Pre-Market: 08:30AM EDT
Thoughts on why the sudden ++AVXL SP in pre market ? Negative as hell yesterday and this AM ,,. new positive pop a few mins ago??
Any rational thoughts on why Dr.M., George, and other informed AVXL consistent posters here have been silent lately? I prefer to think positive on this period of silence, but, not to to the point of excluding fact based observations one might make which might point to an obvious (sitrep)...explanation. TIA
Question: Does SP jitters (when jumping around-up/down) at low S-price indicate anything significant. OR NOT?
toot:
This stock is all hat and no cattle. Please take this mini opportuinity you older duffers to quiet your ambition and sell a huge chunke and get out before you are harmed,
Steady_T
It is easily overwhelmed by the shorts and when the shorting pressure stops the buying pressure starts moving the SP up again.
Any thoughts on what news Tuesday (8/15/23) will/may bring? BTW, today was a nice change.
Reminds me that some posts are non-value add .
learn the game
Taysha (TSHA) doubles on positive Rett results, 150M private placement
I keep telling myself to "follow the science" and ignore the white noise.
Open wish to all for a trash free week of legitimate AVXL info exchange. We are due to have some solid-positive, clinical news any day now.
xodcode:
I'm guessing it's not long now 'til the WGT proponents on this boar will be joined by many!
Our unwritten Goal, AF and his crew are road kill. No prisoners.
Anavex Life Sciences Corp. (AVXL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Following
Visitors trend2W10W9M
Quote Lookup
9.46+0.09 (+0.96%)
As of August 10 09:37AM EDT. Market open.
Maybe the FDA (Amyloid ) story will get the direct-balanced fact based truth now. They have been called out again ...https://bigthink.com/neuropsych/stave-off-alzheimers-protect-brain-mitochondria/.
It is a shame that so much time/money and energy has been spent , this kind of thing should never happen. Curious if the FDA will actually do an analysis-evaluation following their own (published-part 820) required corrective action process rules. What is reason (root cause) for decades of their ineffective corrective action process? This is basic ISO-cGMP management 101 stuff.
Throw another log on the fire.
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/91448832/long-term-clinical-study-demonstrates-disease-modi
Brilliant plan , by abew4me...thanks...it will also open the door as you point out...
Drug repurposing, or repositioning, is a strategy aimed at identifying new uses for already approved drugs, which fall outside their original medical indication. This strategy has led not only to the successful preclinical and clinical testing in multiple neurological disorders,
bas2020
What might the crooks be hiding?
[we were told that Rett and AD readouts will occur within 5 months...if the data is good, we win/
...
Agree w/the spirit of your assertion...BUT...we need to see performance publication/facts that are consistent expectations being set. No More, No Less....it's a credibility thing for me right now. I WANT TO trust ...
pain
The good doctor could not see simple errors in basic stats, you have very high expectations
Sub $7.75 expected by EOD for more reloading
Is this just another TEST? Well, save your breath, most of us do not need one.
Thx George;
Why is This Important? This problem affects the investing public. Whether invested directly in the stock market or in mutual funds, IRAs, retirement or pension plans that hold stock – it touches the majority of Americans. The participants in this fraud, which, when fully exposed, will make Enron look like child’s play, have been very successful in maintaining a veil of secrecy and impenetrability. Congress and the SEC have unknowingly (?) helped keep the closet door closed. The public rarely knows when its pocket is being picked as unexplained drops in stock price get chalked up to “market forces” when they are often market manipulations. The stocks most frequently targeted are those of emerging companies who went to the stock market to raise start-up capital. Small business brings the vast majority of innovative new ideas and products to market and creates the majority of new jobs in the United States. It is estimated that over 1000 of these emerging companies have been put into bankruptcy or had their stock driven to pennies by predatory short sellers.
We'll have to see how or if this develops. Of course, Anavex executives already know the answer, from closed-door murine (lab rodent) studies. This would be blarcamesine's yet unrevealed antiaging property. Might those be restricted only to aging neurons; or, for other body tissues, organs, and processes? Eventually, will everyone be taking a blarcamesine pill each day to maintain youthful health and function deep into life?
August 7th and 8th has a stacked schedule of events, not typical for AVXL. On Monday 8/7 we have the virtual gig and then on Tues 8/8 we have stock holders qtrly. rpt. Stay tuned I guess.
https://finance.yahoo.com/news/anavex-life-sciences-present-btig-113000382.html
So, all we must do is...PAY ATTENTION...THE SYSTEM (CNS) has a LOT TO SAY. We must stop thinking serially....
se·ri·al·ly
adverb
1.
in a series or sequence.
"his stories were published serially in periodicals"
2.
in a way that repeatedly follows a characteristic, predictable behavior pattern.
"a specialist who serially abused the trust of vulnerable patients"
Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and recently a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and recently a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Based on evidence from research on the receptors' function in the brain and the drugs that can activate or inhibit them, the authors propose possible mechanisms by which GABA-modulating treatments could help address the cognitive and affective symptoms associated with depression.
there is very real possibility that the good news brewing is almost at a boil.
Anyone care to speculate on what will happen w/NAS and AVXL SP in particular on 8/3/2003? IMO, we did OK today in-spite of the going NAS melt down.
boi568
Some lies can be considered free speech. You see it on this board every day.
tredenwater2
“When you see what we did you will understand why we did things the way we did them.”
Talon 38. Well done. Watch your 6.
Our competition with Biogen has been going on for years since the MS look.
8.45 +0.20 (+2.42%)
After hours: -...does this count?
TIA